The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation

Prostate

Volumn 71, Issue 15, 2011, Pages 1608-1615

  Keizman, Daniel ^a   Huang, Peng ^a   Antonarakis, Emmanuel S ^a   Sinibaldi, Victoria ^a   Carducci, Michael A ^a   Denmeade, Samuel ^a   Kim, Jenny J ^a   Walczak, Janet ^a   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

disease progression; intermittent androgen deprivation therapy; non metastatic biochemically relapsed prostate cancer; PSA doubling time; serum testosterone

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICALLY RELAPSED PROSTATE CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CASTRATION; HUMAN; INTERMITTENT ANDROGEN DEPRIVATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; TIME FACTORS;

EID: 80053201964     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21377     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC,. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416-419. (Pubitemid 32652213)
3. Zietman AL, Coen JJ, Dallow KC, Shipley WU,. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995; 32: 287-292.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597. (Pubitemid 29211767)
5. Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES,. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005; 23: 826-831. (Pubitemid 46224182)
6. Prapotnich D, Cathelineau X, Rozet F, Barret E, Mombet A, Cathala N, Sanchez-Salas RE, Vallancien G,. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: Oncological results. World J Urol 2009; 27: 627-635.
7. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439. (Pubitemid 41124175)
8. Antonarakis ES, Trock BJ, Feng Z, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA,. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J Clin Oncol 2009; 27: 15s (Suppl; abstract 5008).
9. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH,. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-1383. (Pubitemid 37220457)
10. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV,. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 6992-6998.
11. Partin AW, Eisenberger MA, Sinibaldi VJ, Humphreys E, Mangold LA, Walsh PC,. Prostate specific antigen doubling time (PSADT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biochemical relapse after radical prostatectomy. J Clin Oncol 2004; 22: 14s (Suppl: abstract 4555).
12. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D,. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-1147. (Pubitemid 38327544)
13. Walsh PC, DeWeese TL, Eisenberger MA,. A structured debate: Immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001; 166: 508-515, discussion 515-516. (Pubitemid 32652233)
14. Tunn UW, Eckart O, Kienle EF, Hillger H,. Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA relapse? First results of the randomized prospective phase III clinical trial EC-507. J Urol 2003; 169 (4 Suppl): 396a. Abstract.
15. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456. (Pubitemid 46630983)
16. Moul JW, Bañez LL, Freedland SJ,. Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park) 2007; 21: 1436-1445. Review. Discussion 1449, 1452-1454. (Pubitemid 350252938)
17. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 2010; 57: 49-59. Review.
18. Keizman D, Carducci MA,. Intermittent androgen deprivation-questions remain. Nat Rev Urol 2009; 6: 412-414. Review.
19. Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, Wachter U, Rüssel C, Altwein J,. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007; 25: 18s (Suppl: Abstract 5015).
20. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C,. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-1277.
21. Tunn UW, Kurek R, Kienle E, Maubach L,. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy. J Urol 2004; 171: 384 (abstract 1458).
22. Schulman CC, Irani J, Morote J, Schalken JA, Montorsi F, Chlosta PL, Heidenreich A,. Testosterone measurement in patients with prostate cancer. Eur Urol 2010; 58: 65-74.
23. Shore ND, Crawford ED,. Intermittent androgen deprivation therapy: Redefining the standard of care ? Rev Urol 2010; 12: 1-11.
24. Strum SB, Scholz MC, McDermed JE,. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy. Oncologist 2000; 5: 45-52. (Pubitemid 30127544)
25. Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI,. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol 2008; 26: 2959-2965.
26. Yu E, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS,. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010; 28: 2668-2673.
27. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-3990. (Pubitemid 46630748)
28. Bates AT, Pickles T, Paltiel C,. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62: 148-153. (Pubitemid 40591936)